Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2025-04-25 Director's Dealing
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document text explicitly details transactions involving shares of BioPorto A/S made by 'personer med ledelsesansvar' (persons discharging managerial responsibilities - PDMRs) such as the Chairman of the Board, CEO, and Chief Legal Officer. The filing references 'artikel 19 i forordning (EU) nr. 596/2014' (Article 19 of MAR), which mandates the disclosure of such insider transactions. This type of mandatory disclosure regarding personal share transactions by directors and executives directly corresponds to the definition of Director's Dealing.
2025-04-25 Danish
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document text explicitly details transactions related to shares in BioPorto A/S made by 'persons discharging managerial responsibilities' (directors and executives) and persons closely associated with them. It references 'Article 19 of Regulation (EU) no. 596/2014', which is the specific EU regulation governing insider transactions and manager dealings. The content lists names, positions (Chair of the Board, CEO, CLO), nature of transaction ('Subscription of new shares'), price, and volume. This perfectly matches the definition of Director's Dealing.
2025-04-25 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document title is "Ledende medarbejderes transaktioner" (Transactions by Leading Employees) and it explicitly details share transactions (Tegning af nye aktier - Subscription of new shares) made by individuals with management responsibility (Formand for bestyrelsen, CEO, CFO, etc.) in BioPorto A/S. This directly corresponds to the definition of Director's Dealing (insider trades by executives). The relevant code is DIRS.
2025-04-25 Danish
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the 'Completion of share capital increase' and details the issuance of new shares, resulting in a 'Change of number of shares and votes.' This directly relates to changes in the company's capital structure and share count. Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA). Although it involves raising capital, the focus is on the resulting change in the share structure, making SHA more specific than 'Capital/Financing Update' (CAP). The document is a formal announcement, not a short notice about a report, so RPA/RNS is not the primary fit.
2025-04-25 English
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement (Meddelelse nr. 12) detailing the successful completion of a capital raise ('rejser 33,5 mio. kr. i ny kapitalrunde') through the issuance of new shares. It explicitly mentions the registration of the capital increase with the Danish Business Authority ('Erhvervsstyrelsen') and the resulting change in the total number of shares and voting rights ('Ændring i antal aktier og stemmer'). This directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a share repurchase (POS) as it is an issuance of new capital.
2025-04-25 Danish
Share Issue/Capital Change 2025
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement (4678 characters) dated April 25, 2025, titled 'BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes'. It explicitly details the completion of a private placement, the registration of a capital increase, and the resulting change in the total number of shares and votes. This content directly relates to financing activities and capital structure changes. While it involves a share issue, the primary focus is the capital raise and the resulting share count update, which aligns best with the 'Capital/Financing Update' (CAP) category. It is not a full report, thus ruling out 10-K or IR. It is more specific than a general Regulatory Filing (RNS).
2025-04-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.